Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Rifaximin

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03820817Phase 1Completed

Rifaximin in Patients With Monoclonal Gammopathy

Showing all 1 trials

Research Network

Common Treatments

  • Rifaximin1

Active Sponsors

  • Emory University1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Igm Monoclonal Gammopathy1
  • Waldenstrom Macroglobulinemia1
  • Monoclonal Gammopathy1
  • Smoldering Waldenstrom Macroglobulinemia1
  • Gammopathy Monoclonal1

Activity Timeline